India has become one of the first countries to introduce cheaper, generic brands of weight loss drugs like Ozempic and Wegovy, but health professionals warn a lack of regulation and oversight is causing problems.
Personalise the news and
stay in the know
Emergency
Backstory
Newsletters
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of…
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the…
Demand for weight-loss drugs has soared in India, home to millions with obesity and Type 2 diabetes.
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts…
